Esophageal and esophagogastric junction cancers, version 1.2015.

Published

Journal Article

Esophageal cancer is the sixth most common cause of cancer deaths worldwide. Adenocarcinoma is more common in North America and Western European countries, originating mostly in the lower third of the esophagus, which often involves the esophagogastric junction (EGJ). Recent randomized trials have shown that the addition of preoperative chemoradiation or perioperative chemotherapy to surgery significantly improves survival in patients with resectable cancer. Targeted therapies with trastuzumab and ramucirumab have produced encouraging results in the treatment of advanced or metastatic EGJ adenocarcinomas. Multidisciplinary team management is essential for patients with esophageal and EGJ cancers. This portion of the NCCN Guidelines for Esophageal and EGJ Cancers discusses management of locally advanced adenocarcinoma of the esophagus and EGJ.

Full Text

Duke Authors

Cited Authors

  • Ajani, JA; D'Amico, TA; Almhanna, K; Bentrem, DJ; Besh, S; Chao, J; Das, P; Denlinger, C; Fanta, P; Fuchs, CS; Gerdes, H; Glasgow, RE; Hayman, JA; Hochwald, S; Hofstetter, WL; Ilson, DH; Jaroszewski, D; Jasperson, K; Keswani, RN; Kleinberg, LR; Korn, WM; Leong, S; Lockhart, AC; Mulcahy, MF; Orringer, MB; Posey, JA; Poultsides, GA; Sasson, AR; Scott, WJ; Strong, VE; Varghese, TK; Washington, MK; Willett, CG; Wright, CD; Zelman, D; McMillian, N; Sundar, H; National comprehensive cancer network,

Published Date

  • February 2015

Published In

Volume / Issue

  • 13 / 2

Start / End Page

  • 194 - 227

PubMed ID

  • 25691612

Pubmed Central ID

  • 25691612

Electronic International Standard Serial Number (EISSN)

  • 1540-1413

Digital Object Identifier (DOI)

  • 10.6004/jnccn.2015.0028

Language

  • eng

Conference Location

  • United States